TITLE

Black Workers At Merck Pharmaceutical Co. Sue Citing Alleged Bias At Pennsylvania Plant

PUB. DATE
February 1999
SOURCE
Jet;02/22/99, Vol. 95 Issue 12, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that several black employees of Merck & Co., the pharmaceutical giant, have filed a class-action federal civil-rights lawsuit against the company's plant in West Point, Pennsylvania. Allegations of a pattern of racial discrimination against black workers; Comments by Robert Vance, attorney for the plaintiffs; Excerpts from Merck's press statement.
ACCESSION #
1547902

 

Related Articles

  • Vioxx ruling won't add to liability cover woes. Bradford, Michael; Parekh, Rupal // Business Insurance;8/29/2005, Vol. 39 Issue 35, p1 

    Reports that the verdict against Merck & Co. Inc. will not have an impact on the liability costs of pharmaceutical companies according to sources from the insurance industry. Effect of drug litigation on the availability and cost of product liability coverage of pharmaceutical companies;...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Oct2005, Vol. 40 Issue 10, p12 

    Focuses on the lawsuit lost by Merck & Co. Inc. to Vioxx users in the U.S. Claims against the side effects of Vioxx; Implications of the case for drug safety and increased statistical risk of heart disease; Concerns of drug companies over the potential side effects of drug discoveries.

  • life sciences In Brief.  // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p13 

    Presents the new concerning the pharmaceutical market as of October 2004 in the United States. Lawsuit filed by Merck & Co. against Dr. Reddy's Laboratories concerning patent infringement on finasteride tablets; Approval received for Ivax Corp.'s fluoxetine capsules and tablets; Licensing and...

  • THE VIOXX SCORECARD.  // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p37 

    The article presents several court cases filed against Merck and Co. in the U.S. by various Americans related to the use of the firm's drug Vioxx. This drug is being used for pain relief and was being studied for its ability to prevent cancer and block the growth of new blood vessels to solid...

  • Sales rep files $100M suit against Merck & Co. Zanki, Tom // njbiz;5/20/2013, p2 

    The article reports on the filing of a 100 million-dollar sex discrimination lawsuit by a Merck & Co. sales representative in May 2013, accusing the New Jersey pharmaceutical company of discriminating against women, especially working mothers and pregnant employees, which the company denies.

  • 95% Off! With a Catch. Mokhiber, Russell // Multinational Monitor;Nov/Dec2007, Vol. 28 Issue 5, p56 

    The article reports that Merck will pay $670 million to settle U.S. federal and state charges that it violated the False Claims Act by engaging in nominal pricing fraud. The settlement is considered as the first in a series of federal cases filed against major pharmaceutical companies that...

  • Merck hopes for home-field advantage in round two. Arnold, Matthew // Medical Marketing & Media;Sep2005, Vol. 40 Issue 9, p8 

    Focuses on the trial of the case "Michael Humeston v. Merck & Co Inc.," where the Humeston's family ordered Merck to pay in punitive damages. Facts of the case; Merits of the case; Contention of the plaintiff; Arguments of the defendant.

  • Battle over Fosamax bursts into court. Moynihan, Ray // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/8/2009, Vol. 339 Issue 7716, p320 

    The article focuses on the controversy surrounding the pharmaceutical company Merck regarding its golden goose alendronic acid drug Fosamax. An estimated 800 plaintiffs allege that Merck's alendronic acid drug caused them to suffer osteonecrosis of the jaw or the dead jaw syndrome. However, the...

  • Merck to pay $58m in settlement over rofecoxib advertising. Charatan, Fred // BMJ: British Medical Journal (International Edition);5/31/2008, Vol. 336 Issue 7655, p1208 

    The article reports on the pharmaceutical company Merck & Co.'s decision to pay $58 million in a settlement related to its rofecoxib (Vioxx) advertising. The company agreed to the settlement to settle allegations that its advertising played down potential health risks associated with the drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics